---
title: "Jinhe Biotechnology's controlling shareholder, Jinhe Holdings, has completed a reduction in holdings, totaling a 3% share reduction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255948874.md"
description: "According to the Zhitong Finance APP, Jinhe Biotechnology announced that the share reduction plan of its controlling shareholder, Jinhe Holdings, has been completed. From August 11, 2025, to September 1, 2025, it reduced its holdings by a total of 22.5631 million shares through block trades and centralized bidding, accounting for 3% of the total share capital of the company after excluding repurchased shares"
datetime: "2025-09-04T11:36:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255948874.md)
  - [en](https://longbridge.com/en/news/255948874.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255948874.md)
---

# Jinhe Biotechnology's controlling shareholder, Jinhe Holdings, has completed a reduction in holdings, totaling a 3% share reduction

According to the Zhitong Finance APP, Jinhe Biotechnology (002688.SZ) announced that the share reduction plan of its controlling shareholder, Jinhe Holdings, has been completed. From August 11, 2025, to September 1, 2025, it reduced a total of 22,563,100 shares of the company through block trades and centralized bidding, accounting for 3% of the total share capital of the company after excluding repurchased shares

### Related Stocks

- [002688.CN](https://longbridge.com/en/quote/002688.CN.md)

## Related News & Research

- [03:00 ETHuion lanza la libreta electrónica Huion Note E: Productividad accesible para empresas y creativos](https://longbridge.com/en/news/287020642.md)
- [Cantonese restaurant Wing Seong Fatty’s to end 100-year run](https://longbridge.com/en/news/286856179.md)
- [Leo Cancer Care Secures CE Mark for Marie®, Advancing Upright Radiotherapy in Europe](https://longbridge.com/en/news/287085225.md)
- [Fast Fashion Giant SHEIN Buys Out Everlane for $100 Million](https://longbridge.com/en/news/286766131.md)
- [First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial](https://longbridge.com/en/news/286888745.md)